These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11799261)

  • 1. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia.
    Nakamura T; Ushiyama C; Hirokawa K; Osada S; Shimada N; Koide H
    Am J Nephrol; 2001; 21(6):449-54. PubMed ID: 11799261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
    Paniagua JA; López-Miranda J; Pérez-Martínez P; Marín C; Vida JM; Fuentes F; Fernández de la Puebla RA; Pérez-Jiménez F
    Diabet Med; 2005 Dec; 22(12):1647-56. PubMed ID: 16401307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
    Tran D; Lowy A; Howes JB; Howes LG
    Diabetes Obes Metab; 2005 May; 7(3):273-81. PubMed ID: 15811145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis.
    Nakamura T; Ushiyama C; Hirokawa K; Osada S; Inoue T; Shimada N; Koide H
    Nephrol Dial Transplant; 2002 May; 17(5):798-802. PubMed ID: 11981066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
    De Luis DA; Romero E; Aller R; Izaola O
    Clin Nutr; 2000 Oct; 19(5):367-70. PubMed ID: 11031077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
    Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients.
    Bruno CM; Meli S; Marcinno M; Ierna D; Sciacca C; Neri S
    J Biol Regul Homeost Agents; 2002; 16(2):114-7. PubMed ID: 12144123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.
    Nakamura T; Ushiyama C; Shimada N; Hayashi K; Ebihara I; Koide H
    J Diabetes Complications; 2000; 14(5):250-4. PubMed ID: 11113686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
    Stein E
    Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia. Hyperlipidaemia in Diabetes Mellitus investigators.
    Rubinstein A; Maritz FJ; Soule SG; Markel A; Chajek-Shaul T; Maislos M; Tal S; Stolero D
    J Cardiovasc Risk; 1999 Dec; 6(6):399-403. PubMed ID: 10817086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia.
    Seligman BG; Biolo A; Polanczyk CA; Gross JL; Clausell N
    Diabetes Care; 2000 Sep; 23(9):1395-400. PubMed ID: 10977040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerivastatin.
    Cheng-Lai A
    Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
    Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K
    Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
    Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
    Stein E
    Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril.
    Vongterapak S; Dahlan W; Nakasatien S; Anuntakulnatee T; Suppanich M; Kittipoom W; Surasingchaidet C; Tamwiwat C; Tepkasetkul M; Bunnag P; Ongphiphadhanakul B; Rajatanavin R; Himathongkam T
    J Med Assoc Thai; 1998 Sep; 81(9):671-81. PubMed ID: 9737124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus.
    Zanatta CM; Gerchman F; Burttet L; Nabinger G; Jacques-Silva MC; Canani LH; Gross JL
    Diabetes Res Clin Pract; 2008 May; 80(2):299-304. PubMed ID: 18346810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
    Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
    J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
    Scharnagl H; Stojakovic T; Winkler K; Rosinger S; März W; Boehm BO
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):372-5. PubMed ID: 17701882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLASMA ENDOTHELIN-1 LEVELS AND ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    Zeravica R; Ilincic B; Cabarkapa V; Sakac V; Crnobrnja V; Stosic Z
    Med Pregl; 2016 Oct; 69(5-6):140-145. PubMed ID: 29693840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.